(Total Views: 584)
Posted On: 08/03/2023 4:29:53 PM
Post# of 154989
Seagen has DEprioritized work on Ladiratuzumab Vedotin, ...the biotech quietly disclosed in it second quarter financial report on wednesday.
Seagen had been studying the drug in Breast Cancer...and other solid tumors... alongside Mercks blockbuster inhibitor Keytruda.
In a deal worth upto $4.2 Billion MERCK had paid $600 Million...upfront in 2020 for co-development and co-commercialization rights for the antibody drug conjugate known as LV. ___Endpoint News Aug 3/2023.
Seagen had been studying the drug in Breast Cancer...and other solid tumors... alongside Mercks blockbuster inhibitor Keytruda.
In a deal worth upto $4.2 Billion MERCK had paid $600 Million...upfront in 2020 for co-development and co-commercialization rights for the antibody drug conjugate known as LV. ___Endpoint News Aug 3/2023.
(3)
(0)
